Compare Amgen, Inc. (AMGN) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Hut 8 Corp — how do they compare? Amgen, Inc. trades at $415.25 (market cap $224.14B), while Hut 8 Corp trades at $90.55 (market cap $10.94B). The key difference: Amgen, Inc. is far larger — about 20.5× Hut 8 Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| AMGN | HUT | |
|---|---|---|
Market Cap | $224.14B | $10.94B |
Sector | Health | Technology |
52-Week High | $417.20 | $133.02 |
52-Week Low | $271.18 | $21.37 |
Enterprise Value | $267.45B | $18.38B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
HUT trades at $93.91, up 9.63% today amid a broader neocloud stock rally. The stock shows bearish technical signals with support at $87 and resistance at $92. Fundamentally, revenue grew 81% year-over-year in Q2 2026 to $74 million, but net losses persist with a -188.59% margin. The company is transitioning to an AI data center focus, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (93.75%) and a $165.11 price target reflect optimism in AI infrastructure growth, but high valuation ratios and persistent losses pose risks. Execution on Beacon Point commercialization and debt management are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
